Daniela M. Gioia

Alessandria, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).

Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).

Journal: Hematological oncology
Published: March 13, 2022

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial.

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial.

Journal: Blood advances
Published: May 03, 2021

Correction to: The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatments.

Correction to: The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatments.

Journal: Annals of hematology
Published: November 21, 2020

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.

Journal: Cancer medicine
Published: May 07, 2019

Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study.

Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study.

Journal: Annals of hematology
Published: April 15, 2019

The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.

The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.

Journal: Annals of hematology
Published: April 08, 2019

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Journal: Haematologica
Published: August 05, 2018

Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.

Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.

Journal: Leukemia & lymphoma
Published: May 10, 2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 29, 2017

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 18, 2016

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.

Journal: British journal of haematology
Published: January 17, 2016

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Journal: The Journal of clinical investigation
Published: August 27, 2014
Showing 1-12 of 14

Last Updated: 09/26/2026